Abstract

Canagliflozin (Cana) is an FDA-approved diabetes drug that protects against cardiovascular and kidney diseases. It also inhibits the sodium glucose transporter 2 by blocking renal reuptake and intestinal absorption of glucose. In the context of the mouse Interventions Testing Program, genetically heterogeneous mice were given chow containing Cana at 180 ppm at 7 months of age until their death. Cana extended median survival of male mice by 14%. Cana also increased by 9% the age for 90th percentile survival, with parallel effects seen at each of 3 test sites. Neither the distribution of inferred cause of death nor incidental pathology findings at end-of-life necropsies were altered by Cana. Moreover, although no life span benefits were seen in female mice, Cana led to lower fasting glucose and improved glucose tolerance in both sexes, diminishing fat mass in females only. Therefore, the life span benefit of Cana is likely to reflect blunting of peak glucose levels, because similar longevity effects are seen in male mice given acarbose, a diabetes drug that blocks glucose surges through a distinct mechanism, i.e., slowing breakdown of carbohydrate in the intestine. Interventions that control daily peak glucose levels deserve attention as possible preventive medicines to protect from a wide range of late-life neoplastic and degenerative diseases.

Highlights

  • Aging is the dominant risk factor for most chronic diseases that afflict people in industrialized societies

  • The life span benefit of Cana is likely to reflect blunting of peak glucose levels, because similar longevity effects are seen in male mice given acarbose, a diabetes drug that blocks glucose surges through a distinct mechanism, i.e., slowing breakdown of carbohydrate in the intestine

  • Acarbose, 17aE2, and rapamycin can each produce significant life span extension even when started at ages 60%–70% of the median survival age of controls, i.e., 16–20 months of age [13, 14]

Read more

Summary

Introduction

Aging is the dominant risk factor for most chronic diseases that afflict people in industrialized societies. There is ample evidence, in mice, that the process of aging can be delayed or retarded by low-calorie diets [1,2,3,4,5], by natural or engineered mutations in any of several genes that modify growth hormone and IGF-1 signals [6, 7], and, more recently, by drugs added to food [8] Each of these approaches has been shown to extend life span and to delay multiple forms of late-life illness, including both neoplastic and degenerative diseases. These drugs may provide a starting point for development of antiaging interventions in humans

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.